Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Beta-lapachone Highly Effective Against Non-small Cell Lung Cancer

By Biotechdaily staff writers
Posted on 18 Jul 2007
A recent report described the molecular mechanism used by the chemotherapeutic agent beta-lapachone to kill non-small cell lung cancer (NSCLC) tumors. NSCLC is one of the deadliest forms of cancer with a five-year survival rate of only about 15%.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) studied the action of beta-lapachone on the enzyme NAD(P)H:quinone oxidoreductase-1 (NQO1). NQO1 is absent or nearly absent in normal tissues but highly expressed in NSCLC tumors.

Results published in the July 3, 2007, online edition of the Proceedings of the [U.S.] National Academy of Sciences revealed that NSCLC cells grown in tissue culture were killed by a high dose of beta-lapachone given for only two to four hours. Normal cells not expressing NQO1 were not damaged by the drug.

Beta-lapachone induced formation of active radicals that caused damage to the cancer cells' DNA while at the same time disrupting the cells' ability to repair their DNA (by inhibiting the DNA repair enzyme topoisomerase I), ultimately leading to the death of the cells. Since treating tumor cells with radiation also causes DNA damage, co-treatment with radiation and beta-lapachone was even more effective than treatment with the drug alone.

"When you irradiate a tumor, the levels of NQO1 go up,” said senior author Dr. David Boothman, professor of pharmacology and radiation oncology at the University of Texas Southwestern Medical Center. "When you then treat these cells with beta-lapachone, you get synergy between the enzyme and this agent and you get a whopping kill. Basically, we have worked out the mechanism of action of beta-lapachone and devised a way of using that drug for individualized therapy.”


Related Links:
University of Texas Southwestern Medical Center

Channels

Genomics/Proteomics

view channel
Image: Bacteriophage EFDG1 visualized by transmission electron microscopy (TEM) at a magnification of 20,000–30,000 times. Note that some phages are still bound to remains of the dead bacteria (Photo courtesy of the Hebrew University of Jerusalem).

Bacteriophage Therapy Eliminates Multidrug Resistant Bacterial Infections

Bacteriophage therapy has been shown to be an effective approach for treating infections caused by drug-resistant strains of the bacterium Enterococcus faecalis. E. faecalis, a bacterium inhabiting... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.